Retinoblastoma Treatment Market Size & Share 2025 – 2034

Retinoblastoma Treatment Market Size

The global retinoblastoma treatment market size was valued at around USD 1.6 billion in 2024 and is estimated to grow at 5% CAGR from 2025 to 2034, owing to the rising incidence of retinoblastoma, advancements in targeted therapies, innovations in ocular oncology, and increased early diagnosis and awareness programs.

As the global prevalence of retinoblastoma increases, the demand for effective treatment solutions also rises. For instance, according to the National Institute of Health (NIH), approximately 9,000 individuals are diagnosed with retinoblastoma each year across the world. This increase in volume of patients increases the need for new and effective treatment solutions, which is driving the growing retinoblastoma treatment market.
 

Moreover, the increasing occurrence of this chronic illnesses has underscored the need for new strategies to tackle these alarming concerns. Many institutions are focusing on research and development to create new treatment options that would satisfy this increased demand. For instance, in August 2024, Theriva Biologics’ received Rare Pediatric Drug Designation (RPDD) grant from the U.S. Food and Drug Administration for VCN-01 treatment for retinoblastoma. Such developments are expected to significantly boost the market growth over the forecast period.
 

Retinoblastoma is a rare type of ocular cancer affecting retina, the light-sensing tissue at the back of the eye. This cancer can affect a single or both eyes of the patient. In about 25% of cases, it affects both eyes. It occurs mostly in young children and is diagnosed before the age of 2.
 

Retinoblastoma Treatment Market Trends

• The shift towards targeted treatments, such as proteasome inhibitors (carfilzomib) and histone deacetylase (HDAC) inhibitors (vorinostat), is promoting the development of these drugs for treating advanced retinoblastoma.
   
• The advent of telemedicine and mobile health applications are boosting the diagnosis and treatment of retinoblastoma patients remotely. Technologies such as deep learning and AI-enabled retinal imaging are improving early screening and detection of retinoblastoma, particularly in remote areas where resources are limited.
   
• Furthermore, efforts to avoid eye removal (enucleation) and vision loss by using new treatment options are increasing. For example, focal therapies, such as cryotherapy, thermotherapy, and photocoagulation, are gaining popularity for treating early-stage ocular tumors.
   

Retinoblastoma Treatment Market Analysis

In 2021, the global market was valued at USD 1.48 billion. The following year, it saw a slight increase to USD 1.53 billion, and by 2023, the market further climbed to USD 1.58 billion. Based on disease type, the market is bifurcated into non-hereditary retinoblastoma and hereditary retinoblastoma. The non-hereditary retinoblastoma segment dominated the market with the largest revenue share of 80.3% in 2024 and is expected to grow at a CAGR of 5.1% over the forecast period.
 

• The increasing prevalence of non-hereditary retinoblastoma is driving the segmental growth. For instance, according to the NIH, almost 90% of all unilateral retinoblastoma cases are non-hereditary. This high volume of cases is driving the demand for effective treatment options, facilitating segment growth.
   
• Additionally, investments in pediatric oncology programs to provide widespread access to non-hereditary retinoblastoma care in developing countries is driving segment growth.
   

Based on disease stage, the retinoblastoma treatment market is bifurcated into intraocular retinoblastoma and extraocular retinoblastoma. The intraocular retinoblastoma segment dominated the market with the largest revenue of USD 1.2 billion in 2024 and is expected to reach USD 2 billion by 2032.
 

• The increasing cases of intraocular retinoblastoma are driving the demand for effective treatment options. For instance, according to NIH, intraocular retinoblastoma accounts for approximately 3% of all childhood tumor cases.
   
• Additionally, the growing adoption of intravitreal chemotherapy and intra-arterial chemotherapy to reduce systemic toxicity is boosting segment growth.
   

Based on treatment type, the retinoblastoma treatment market is segmented into chemotherapy, radiation therapy, surgery, laser therapy, and cryotherapy. The chemotherapy segment dominated the market with the largest revenue of USD 658.1 million in 2024 and is expected to grow at a CAGR of 5.1% over the forecast period.
 

• The increasing adoption of intravitreal and intra-arterial chemotherapy, due to its reduced side-effects, is driving segment growth. For instance, according to Cancer Research and Treatment, intra-arterial chemotherapy (IAC) has been a standard treatment option for eye preservation since its introduction.
   
• Additionally, the fast-tracked approval and incentives for chemotherapy agents and drugs by regulatory organizations are driving the segment growth. For instance, in October 2020, Oxular Limited announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug and Rare Pediatric Disease designations for its OXU-003.
   

Based on end use, the retinoblastoma treatment market is segmented into hospitals, cancer treatment center, and specialty eye clinics. The hospitals segment dominated the market with the largest revenue of USD 685.9 million in 2024 and is expected to grow at a CAGR of 5% over the forecast period.
 

• Hospitals are increasingly investing in specialized pediatric ophthalmology and oncology units, alongside the integration of genetic specialists, ophthalmologists, and oncologists, which is driving the growth of hospital-based retinoblastoma treatment.
   
• Additionally, the increasing integration of chemotherapy centers in hospitals settings in driving the segment growth.
   

The U.S. dominates the North American retinoblastoma treatment market and holds the largest market share in 2024. The market revenue in the U.S. has increased considerably from USD 525.5 million in 2024 and is expected to grow significantly, reaching USD 843.4 million by 2034.
 

• The U.S. faces an increasing number of retinoblastoma cases, primarily due to the increasing risk of RB1 gene mutations among children. For instance, according to the American Cancer Society, approximately 200 to 300 children in the U.S. are diagnosed with retinoblastoma annually. The increasing need to reduce the number of cases in the pediatric population is driving the demand for treatment options in the region.
   
• Additionally, organizations in the country such as the National Cancer Institute and the American Cancer Society promote early diagnosis via various awareness programs and initiatives, driving the demand for effective treatment options.
   
• Furthermore, the presence of numerous prominent organizations that promote cancer research, including the National Institutes of Health, St. Jude Children’s Research Hospital, Children’s Oncology Group (COG), and Memorial Sloan Kettering Cancer Center, is facilitating the development of novel retinoblastoma treatments, driving market growth.
   

Europe: The retinoblastoma treatment market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• Various organizations in the country are promoting early detection of retinoblastoma for improved treatment outcomes through partnerships and public health initiatives. For instance, the Childhood Eye Cancer Trust (CHECT) is a charity organization in the UK that helps patients affected by retinoblastoma. The growing efforts of such organizations are driving the market growth in the country.
   
• Additionally, retinoblastoma is one of the most common pediatric cancers in the UK despite its low occurrence. For instance, according to the Childhood Eye Cancer Trust, approximately 40-50 new cases of retinoblastoma are diagnosed in children each year in the UK. The high survival rate of 98% for retinoblastoma promotes patient confidence in the treatments, boosting its adoption in the region.
   

Asia Pacific: Japan retinoblastoma treatment market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The mean age of childbearing is one of the highest in Japan. For instance, according to Statista, the mean age of parents at childbirth was 31.4 years in 2021, one of the highest in the world. This increases the chances of genetic mutations among children and the risks associated with retinoblastoma. This demographic factor is driving the growth of the market in the country.
   
• Additionally, growing initiatives and campaigns related to the research and development of personalized and novel treatment options for retinoblastoma by organizations such as the Japan Agency for Medical Research and Development (AMED) and Rikagaku Kenkyusho - The Institute of Physical and Chemical Research (RIKEN) are driving market growth.
   

Middle East and Africa: The retinoblastoma treatment market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The high presence of consanguineous marriages in Saudi Arabia, causing hereditary genetic mutations, is driving retinoblastoma incidence in the country. For instance, according to the American Academy of Ophthalmology, approximately 25 new cases of retinoblastoma are diagnosed each year in Saudi Arabia. The high prevalence coupled with the growing importance of genetic screening programs, is driving the market growth.
   
• Additionally, initiatives by the Saudi government for investments in cancer research and clinical trials for the development of novel retinoblastoma treatment are facilitating market growth in the country. For instance, organizations such as the Saudi Cancer Society and King Saud University are constantly conducting various trials and research aimed at the development of advanced treatment options for retinoblastoma.
   

Retinoblastoma Treatment Market Share

The market is competitive, with Baxter International, GlaxoSmithKline, Johnson & Johnson, and Novartis holding approximately 45% of the market share. The market is competitive, featuring both major global companies and numerous smaller firms. Companies are investing in developing advanced retinoblastoma treatments, such as nanotechnology-based therapies, topical drug delivery systems, and biomaterial innovations to improve treatment outcomes. Strategic partnerships with research institutions and healthcare providers are crucial for integrating modern technologies and expanding distribution, enabling companies to address the rising demand for these services. Regulatory support and streamlined approval processes further drive innovation and market entry, solidifying the position of firms within the growing market.
 

Retinoblastoma Treatment Industry News:

• In October 2024, Advancium Health announced the acquisition of ALRN-6924, an oncology agent for the treatment of retinoblastoma, from Aileron Therapeutics, Inc. The acquisition was expected to expand Advancium Health’s reach in the market and introduce novel treatment options.
   
• In July 2024, the U.S. Food and Drug Administration (FDA) granted rare pediatric drug designation to Theriva Biologics’ VCN-01 for the treatment of retinoblastoma in pediatric patients. This initiative highlighted the immediate need for retinoblastoma treatments. This designation approval was expected to expand the company’s reach in the market through the introduction of novel treatments.
   
• In October 2020, Oxular Limited announced that the FDA granted orphan drug designation and rare pediatric disease designation for its OXU-003, a novel drug under development for the treatment of retinoblastoma. This designation approval was expected to promote the development of novel treatments, boosting the company’s share in the market.
   
• In October 2024, Theriva Biologics announced that its VCN-01 , a stroma-degrading, selective, systemic oncolytic adenovirus, was granted orphan medical product designation by the European Commission. This approval provided Theriva Biologics with an opportunity to introduce novel retinoblastoma treatments in the European market.
   

Retinoblastoma Treatment Market Companies

Some of the eminent market participants operating in the retinoblastoma treatment industry include:

• Advancium Health
• Baxter International
• Bristol-Myers Squibb Company
• Cadila Pharmaceuticals
• Cellceutix Corporation
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co.
• Novartis
• Pfizer
• Teva Pharmaceutical Industries
• Theriva Biologics
   
• GlaxoSmithKline is one of the leading players in the market. The company has extensive research and development capabilities engaged in the development of novel treatments for retinoblastoma treatment.
   
• Pfizer is another major player in the market. The company’s broad portfolio of chemotherapy drugs intended for retinoblastoma treatment, including topotecan hydrochloride injection and carboplatin injection, solidify its position as one of the leading cancer treatment drugs organizations.
   

The retinoblastoma treatment market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Disease Type

• Non-hereditary retinoblastoma
• Hereditary retinoblastoma

Market, By Disease Stage

• Intraocular retinoblastoma
• Extraocular retinoblastoma

Market, By Treatment Type

• Chemotherapy
• Radiation therapy
• Surgery
• Laser therapy
• Cryotherapy

Market, By End Use

• Hospitals
• Cancer treatment center
• Specialty eye clinics

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE